Overview
As demand for GLP-1 medications continues to grow, employers face important questions about long-term effectiveness, rising costs, and sustainable weight management outcomes. This white paper examines employee behaviors, prescribing patterns, and treatment expectations to uncover where current approaches may fall short. You'll learn why obesity requires more than medication alone, how integrated care teams improve support, and what employees say they need to succeed. Through survey findings, clinical insights, and real-world outcomes from Levanto's Healthy Weight program, the paper outlines four practical strategies for building a more effective obesity care benefit.
Complete Form to Download
GLP-1 medications have created unprecedented interest in obesity treatment—and unprecedented spending for employers. Yet new employee survey data reveals a critical disconnect: many employees view these medications as short-term solutions, while obesity remains a chronic condition requiring long-term support. In this white paper, benefits leaders will gain insight into how employees are accessing GLP-1s, how long they expect to stay on them, and why behavior change remains essential to sustainable outcomes. You'll also explore practical strategies for integrating primary care, behavioral science, coaching, and medication management into a more comprehensive approach. Download the full paper to discover how leading organizations can improve health outcomes, reduce fragmentation, and maximize the value of their weight management investments.
